Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V; PERICO Study Group. Labarga P, et al. Among authors: terron a. J Infect Dis. 2012 Sep 15;206(6):961-8. doi: 10.1093/infdis/jis449. Epub 2012 Jul 17. J Infect Dis. 2012. PMID: 22807523 Clinical Trial.
Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment.
Mira JA, Lozano F, Santos J, Ramayo E, Terrón A, Palacios R, León EM, Márquez M, Macías J, Fernández-Palacin A, Gómez-Mateos J, Pineda JA; Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Mira JA, et al. Among authors: terron a. Antivir Ther. 2004 Aug;9(4):511-7. Antivir Ther. 2004. PMID: 15456082 Clinical Trial.
Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C.
Mira JA, Macías J, Girón-González JA, Merino D, González-Serrano M, Jiménez-Mejías ME, Caballero-Granado FJ, Torre-Cisneros J, Terrón A, Becker MI, Gómez-Mateos J, Arizcorreta-Yarza A, Pineda JA; Grupo Andaluz Para el Estudio de las Enfermedades Infecciosas (GAEI). Mira JA, et al. Among authors: terron a. J Antimicrob Chemother. 2006 Jul;58(1):140-6. doi: 10.1093/jac/dkl214. Epub 2006 May 23. J Antimicrob Chemother. 2006. PMID: 16720565
Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
Mallolas J, Blanco J, Labarga P, Vergara A, Ocampo A, Sarasa M, Arnedo M, López-Púa Y, García J, Juega J, Guelar A, Terrón A, Dalmau D, García I, Zárraga M, Martínez E, Carné X, Pumarola T, Escayola R, Gatell J. Mallolas J, et al. Among authors: terron a. HIV Med. 2007 May;8(4):226-33. doi: 10.1111/j.1468-1293.2007.00464.x. HIV Med. 2007. PMID: 17461850 Free article. Clinical Trial.
Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C.
Vispo E, Labarga P, Guardiola JM, Barreiro P, Miralles C, Rubio R, Miralles P, Aguirrebengoa K, Portu J, Morello J, Rodriguez-Novoa S, Soriano V; PERICO Study Group. Vispo E, et al. AIDS Res Hum Retroviruses. 2010 Apr;26(4):419-24. doi: 10.1089/aid.2009.0120. AIDS Res Hum Retroviruses. 2010. PMID: 20377423 Clinical Trial.
Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.
Estrada V, Geijo P, Fuentes-Ferrer M, Alcalde ML, Rodrigo M, Galindo MJ, Muñoz A, Domingo P, Ribera E, Cosín J, Viciana P, Lozano F, Terrón A, Vergara A, Teira R, Muñoz-Sánchez J, Roca B, Sánchez T, López-Aldeguer J, Deig E, Vidal F, Pedrol E, Castaño-Carracedo M, Puig T, Garrido M, Suárez-Lozano I. Estrada V, et al. Among authors: terron a. BMC Womens Health. 2011 Aug 4;11:36. doi: 10.1186/1472-6874-11-36. BMC Womens Health. 2011. PMID: 21816091 Free PMC article.
Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients.
Macías J, Neukam K, Mallolas J, López-Cortés LF, Cartón JA, Domingo P, Moreno S, Iribarren JA, Clotet B, Crespo M, de Los Santos I, Ortega E, Knobel H, Jiménez-Expósito MJ, Pineda JA; COINS Study Team. Macías J, et al. HIV Clin Trials. 2012 Mar-Apr;13(2):61-9. doi: 10.1310/hct1302-61. HIV Clin Trials. 2012. PMID: 22510353
CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study.
Valero IP, Pasquau J, Rubio R, Ribero A, Santos J, Sanz J, Mariño A, Crespo M, Hernandez J, Iribarren JA, Gutierrez F, Terron A, Esteban H, Pérez-Molina JA. Valero IP, et al. Among authors: terron a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19656. doi: 10.7448/IAS.17.4.19656. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394160 Free PMC article.
287 results